ATE518954T1 - Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen - Google Patents

Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen

Info

Publication number
ATE518954T1
ATE518954T1 AT05774823T AT05774823T ATE518954T1 AT E518954 T1 ATE518954 T1 AT E518954T1 AT 05774823 T AT05774823 T AT 05774823T AT 05774823 T AT05774823 T AT 05774823T AT E518954 T1 ATE518954 T1 AT E518954T1
Authority
AT
Austria
Prior art keywords
interfering rna
small interfering
ribonucleotide reductase
rna molecules
molecules against
Prior art date
Application number
AT05774823T
Other languages
English (en)
Inventor
Aiping Young
Jim Wright
Original Assignee
Lorus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lorus Therapeutics Inc filed Critical Lorus Therapeutics Inc
Application granted granted Critical
Publication of ATE518954T1 publication Critical patent/ATE518954T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT05774823T 2004-08-18 2005-08-18 Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen ATE518954T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60282404P 2004-08-18 2004-08-18
PCT/CA2005/001258 WO2006017932A1 (en) 2004-08-18 2005-08-18 Small interfering rna molecules against ribonucleotide reductase and uses thereof

Publications (1)

Publication Number Publication Date
ATE518954T1 true ATE518954T1 (de) 2011-08-15

Family

ID=35907196

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05774823T ATE518954T1 (de) 2004-08-18 2005-08-18 Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen

Country Status (5)

Country Link
US (1) US20080255065A1 (de)
EP (1) EP1786905B1 (de)
AT (1) ATE518954T1 (de)
CA (1) CA2577036A1 (de)
WO (1) WO2006017932A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2553211A1 (en) * 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
ATE541928T1 (de) * 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
WO2008026946A2 (en) * 2006-08-30 2008-03-06 Genesis Research And Development Corporation Limited Compositions and methods for the treatment and prevention of neoplastic disorders
US20130331294A1 (en) * 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
WO2010027279A2 (en) * 2008-09-04 2010-03-11 Genesis Research And Development Corporation Limited Compositions and methods for the treatment and prevention of neoplastic disorders
WO2012052258A1 (en) 2010-10-18 2012-04-26 Arrowhead Research Corporation Compositions and methods for inhibiting expression of rrm2 genes
JP6165723B2 (ja) 2011-06-30 2017-07-19 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
US20140037573A1 (en) * 2012-02-22 2014-02-06 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
KR102298475B1 (ko) 2013-10-04 2021-09-06 노파르티스 아게 ＲＮＡ 간섭에 사용하기 위한 ＲＮＡｉ 작용제를 위한 3' 말단 캡
EP3052627B1 (de) 2013-10-04 2018-08-22 Novartis AG Neuartige formate für organische verbindungen zur verwendung bei rna-interferenz
JP6546161B2 (ja) 2013-10-04 2019-07-17 ノバルティス アーゲー Ｂ型肝炎ウイルスを治療するための有機化合物
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593305B1 (en) * 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
CA2262776C (en) * 1996-08-02 2005-03-08 Genesense Technologies, Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6121000A (en) * 1999-02-11 2000-09-19 Genesense Technologies, Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
EP1235842A4 (de) 1999-10-15 2003-04-23 Univ Massachusetts Gene des rns-interferenzweges als hilfsmittel der gezielten gentischen interferenz
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
TW480840B (en) * 2000-10-17 2002-03-21 Acer Inc Remote control system
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20040006035A1 (en) * 2001-05-29 2004-01-08 Dennis Macejak Nucleic acid mediated disruption of HIV fusogenic peptide interactions
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
US20040068763A1 (en) * 2002-03-29 2004-04-08 Nancy Hopkins Developmental mutations in zebrafish
FR2838124B1 (fr) * 2002-04-03 2004-05-28 Sanofi Synthelabo Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
JP2006518344A (ja) * 2003-02-10 2006-08-10 ジェネセンス テクノロジーズ インク リボヌクレオチド還元酵素ｒ２を指向するアンチセンスオリゴヌクレオチドおよび癌の治療におけるこれらの使用
CA2553211A1 (en) * 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
ATE541928T1 (de) * 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen

Also Published As

Publication number Publication date
EP1786905A4 (de) 2008-08-20
WO2006017932A1 (en) 2006-02-23
EP1786905A1 (de) 2007-05-23
US20080255065A1 (en) 2008-10-16
CA2577036A1 (en) 2006-02-23
EP1786905B1 (de) 2011-08-03

Similar Documents

Publication Publication Date Title
EP1786905A4 (de) Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen
AU2003261231A8 (en) Modified small interfering rna molecules and methods of use
DK1866414T3 (da) Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf.
GB2439228A (en) Electromagnetic device with integral non-linear component
MXPA06002890A (es) Anticuerpo antiglipicano 3.
WO2008070477A3 (en) Polymeric short interfering rna conjugates
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
JO3134B1 (ar) مثبطات نشاط akt
WO2005076999A3 (en) Methods and compositions for combination rnai therapeutics
ATE446509T1 (de) Serumfreie expansion von zellen in kultur
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
WO2005069987A3 (en) Amplifying interfering rna (rnai) expression and effects
EP2055789A4 (de) Primer-set zur verstärkung des cyp2c19-gens, reagens zur verstärkung des cyp2c19-gens damit und anwendung davon
IL313116A (en) Modification templates for small interfering RNA molecules with high stability and gene silencing activities
GEP20115356B (en) Metastin derivatives and use thereof
AU312245S (en) Writing instrument
DK1773420T3 (da) Anvendelse af gingivale fibroblaster til vaskulær celleterapi
WO2006029161A3 (en) Cell specific gene silencing using cell-specific promoters in vitro and in vivo
ZA200801359B (en) Inhibitors of cancer cell, T-cell and keratinocyte proliferation
WO2006086638A3 (en) Targeting lipocalin-2 for cancer therapeutics
EA200870158A1 (ru) Лечение вич
DE602006007777D1 (de) Reductase Gen und dessen Verwendung
EP2078747A4 (de) Primer-set zur verstärkung des nat2-gens, reagens zur verstärkung des nat2-gens damit und anwendung davon
DK1554381T3 (da) Posttranskriptionel silencing af vævsfaktorekspression med korte interfererende RNA'er
WO2008100922A3 (en) Methods and compositions related to prefoldin and its regulation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties